Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CCR2 | P41597 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | UBE2N | P61088 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11200775 | 0.83 | ITGB2 (0.48) | CYP1A2CCR2IDO1TSHRALDH1A1 | |
| SCHEMBL5185226 | 0.82 | CYP1A2 (0.49) | CYP2D6CYP1A2TDP1TSHRALDH1A1 | |
| SCHEMBL18129367 | 0.82 | CYP1A2 (0.49) | CYP2D6CYP1A2TDP1TSHRALDH1A1 | |
| SCHEMBL11206840 | 0.78 | ALDH1A1 (0.47) | CYP2D6CYP1A2CCR2TDP1IDO1 | |
| SCHEMBL5576227 | 0.77 | CYP1A2 (0.50) | CYP2D6CYP1A2TSHRALDH1A1CYP3A4 | |
| SCHEMBL5853005 | 0.76 | HPGD (0.47) | CYP2D6CYP1A2TDP1TSHRALDH1A1 | |
| SCHEMBL13321630 | 0.74 | CYP1A2 (0.43) | CYP2D6CYP1A2CCR2TDP1ALDH1A1 | |
| SCHEMBL4265450 | 0.73 | TDP1 (0.49) | CYP2D6CYP1A2TDP1ALDH1A1CYP3A4 | |
| SCHEMBL11214254 | 0.73 | TDP1 (0.56) | CYP1A2TDP1ALDH1A1CYP3A4NR2F2 | |
| SCHEMBL7268486 | 0.72 | HPGD (0.58) | CYP2D6TDP1TSHRALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0933354-B1 | CALCIUM RECEPTOR-ACTIVE COMPOUNDS | KYOWA HAKKO KIRIN CO LTD (JP) | 2011-03-30 | — | — | EP | disclosed |
| US-7816408-B2 | Calcium receptor active compounds | NPS PHARMACEUTICALS, INC. (US) | 2010-10-19 | — | — | US | disclosed |
| US-20090176993-A1 | Calcium receptor active compounds | NPS PHARMACEUTICALS, INC. | 2009-07-09 | — | — | US | disclosed |
| US-6939895-B2 | Calcium receptor-active compounds | NPS PHARMACEUTICALS, INC. (US) | 2005-09-06 | — | — | US | disclosed |
| US-6750255-B2 | SUCH AS (R)-N-(1-(1'-NAPHTHYL)ETHYL)-2-(2',5'-DICHOROPHENYL THIO)ETHYLAMINE; FOR STIMULATION OF SECRETION OF PARATHYROID HORMONE | NPS PHARMACEUTICALS, INC. | 2004-06-15 | — | — | US | disclosed |
| US-20030176485-A1 | Calcium receptor active compounds | NPS PHARMACEUTICALS, INC. | 2003-09-18 | — | — | US | disclosed |
| US-20030144526-A1 | Calcium receptor-active compounds | NPS PHARMACEUTICALS, INC. | 2003-07-31 | — | — | US | disclosed |
| US-20020107406-A1 | Calcium receptor-active compounds | NPS PHARMACEUTICALS, INC. (US) | 2002-08-08 | — | — | US | disclosed |
| US-6362231-B1 | MODULATOR OF PARATHYROID HORMONE; OSTEOPOROSIS | NPS PHARMACEUTICALS, INC. | 2002-03-26 | — | — | US | disclosed |
| EP-0933354-A1 | CALCIUM RECEPTOR-ACTIVE COMPOUNDS | KIRIN BEER KABUSHIKI KAISHA (JP) | 1999-08-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144526-A1 | Calcium receptor-active compounds | CASR, CALCR, CNR1 | CYP2D6 1131/4885CYP1A2 2185/4885CCR2 284/4885 |
| US-20090176993-A1 | Calcium receptor active compounds | CASR, CALCR, CACNA1E | CYP2D6 1873/4885CYP1A2 2127/4885CCR2 816/4885 |
| US-20030176485-A1 | Calcium receptor active compounds | CASR, CNR1, CALCR | CYP2D6 1078/4885CYP1A2 2113/4885CCR2 256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.